Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone.
A new market research report by Transparency Market Research, titled “Postmenopausal Vaginal Atrophy Treatment & Drug Market – Global Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 – 2019,” presents an extensive evaluation of the market on the basis of both revenue and volume.
For specifics on vaginal atrophy treatment new york city visit that page.
The global postmenopausal vaginal atrophy treatment and drug market is growing due to the increasing percentage of aging population and the introduction of top non-estrogen-based drugs such as Vaginorm and Osphena. In addition, the enhancement of the healthcare reforms for meeting the requirements to treat vaginal atrophy is also a chief factor fuelling the development of the market. However, the introduction of a number of economically priced generic medicines may inhibit the growth of this market in the coming years.
The competition in the market has been assessed by utilizing the Porter’s five forces model and a detailed explanation of the driving factors, the macro-economic indicators, and the key trends is also encapsulated in this study. A number of market dynamics have also been elaborated coupled with presenting their impact on the development of the postmenopausal vaginal atrophy treatment and drug market. All the major trends in the market have been researched independently for providing a qualitative evaluation of their implications.
The report begins by presenting the introduction of the market encapsulating the definition, causes, and treatment options for postmenopausal vaginal atrophy. Vaginal atrophy is an inflammatory disease of the vagina owing to the shrinking and thinning of the vaginal tissues. The key cause of this disease is the reproductive hormone, estrogen’s, absence. This naturally happens at the pre-menopause stage and can become aggravated in the post menopause phase. At present, Estrace, Premarin, Estring, Colpotrophine, and Vagifem, are amongst the chief branded drugs utilized for the treatment of vaginal atrophy.
On the basis of drug class and analysis, the report segments the market into systemic estrogen and systemic estrogen. Amongst these, the topical estrogen supplies comprise vaginal tablets, vaginal rings, and vaginal creams. Geographically, the report segments the global postmenopausal vaginal atrophy treatment and drug market into North America, Europe, Asia Pacific, and Rest of the World (RoW).
In the last sections of the report, an evaluation of the future and current competition in the market has been presented. According to the report, Novartis, Allergan, Bristol Myers, Pfizer, Mylan, Merck & Co., Inc., and Teva Pharmaceuticals, among others, are the chief players dominant in the global postmenopausal vaginal atrophy treatment and drug market.
Source: Free Articles from ArticlesFactory.com